Ebb & Flow

Investors tired of waiting for two promised large-scale bioinformatics deals from Lion hammered the stock last week, sending it to a 2002 low of E10.47 on Thursday. Over the week, LIO lost E3.2 (23%) to E10.7, pushing its market cap down to E201 million ($175 million).

Several analysts downgraded the stock last week, as a result of LIO's third quarterly report on Feb. 6. With figures just meeting expectations, analysts are worried about earnings prospects, and they continued to express doubts about LIO's bioinformatics business model...